It is probably true that copper prices will rise sometime in the future. In the meantime, Freeport-McMoran has a huge debt and is experiencing huge quarterly losses. When (and, of course, if) Freeport can no longer make its payments on the debt, the creditors will take over the company.
Current shareholders, in such an eventuality, would not enjoy the fruits of the enormous copper deposits that Freeport has, the new owners (i.e. the former creditors who took over the assets) would.
Icahn might be a genius but other billionaire investors have made losing bets on risky investments.
P.S. A buy of fcx stock three days ago (and a sell at the open yesterday, Friday) would have been a great move; however, it might be too late now. At least now it is much riskier, since there was a dumping and an ominous dark candle created on Friday.
The last week or two the price seems stronger even in the face of a withering selloff in the general market. Who knows, maybe something good is finally happening.
Disclaimer: After taking a big loss slightly above $1, I rebuilt and even doubled my stake at an average of $.47. I have all the rxii I need now and will not be buying more, but I have no intention of selling unless there is very bad news.
Big fish in small pond. Growing both in earnings an dividends. Safe, mostly single family home mortgages at no more than 70% loan to value. Dividend payout less than 50%.
With a small stock like this, when there are few orders, it is programmed with a large spread. Then, if you put a sell order at the asked, the asked will fall and if you put a buy order in at the bid, the bid will rise. Once trading picks up, the program will narrow the spread.
There is probably never a human being actually looking at rxii and changing the bid/asked. It's all a matter of supply/demand as measured by the order volume. The program just works off of an algorithm. Also, the computer program triggers buy/sell orders from the market makers when there are no orders from investors.
Well, if biotechpicklist is right about it being so probable that things will go well (and his argument makes sense), there will likely be money made available from somewhere. Anyway, that's my optimistic view at this late hour.
This time sabaidii made a good point.ncoomodorelckc said the stock only went up 3 cents on news, but there was no news. That was sabaidii's point.
Maybe we should all focus on rxii and worry less about our likes and dislikes for one another. This is getting to be too much like a squabble festival, imo.
If Samcyprone were able to prevent the onset or halt further metastasis of cutaneous melanoma it would be amazing and wonderful. There is to my knowledge no truly effective drug against metasticized melanoma and no effective drug to prevent onset of metastasis. Surgical removal of a melanoma is about all that can be done, and that must be done before metastasis. Even that is iffy because it is not always clear that the discoverd melanoma was a primary occurence, rather than an already metasticized occurence. Chemotherapy is not effective at all and Interferon has less than a 10% cure rate.
My son in law died of ocular melanoma--which I realize is not cutaneous melanoma but it is closely related--and it was heart wrenching to know that medical science had come up with no way to help him. Not only would such a break through put Rxi Pharma through the roof, it would be a great gift to the world.
I think participant's point was that merely copying and posting required disclaimers (which all stocks have) as if that was revealing and relevant to determining value relative to peers is nonsense. The resident naysayers around here do that a lot. There is nothing wrong with bears posting relevant cautionary stuff but when they post what occurs on all Q's and suggest it casts particular doubt on rxii, they are out of line.
biotechpicklist, bi0technician, rmsacc, tene, autumn, participant, and other bulls here--including myself to an extent--see a bright future for rxii. They see a breakthrough technology with sd-rxrnai; much promise with Samcyprone; a brilliant and proven ceo and very distinguished and knowledgeable associates and advisers; targets which represent unmet needs; other biotechs eyeing rxii as a juicy takeover, out licensor, or partner; etc. The future looks very bright indeed, if not almost guaranteed, to those with such a slant on things.
Why then, is the stock at $.36, just teetering on the all time low and with a chart that looks like the giant slide at an amusement park? I think it is because the perspective of all but the hard core bulls is different. The market in general sees a tiny company of fifteen or so people; an ever increasing number of shares due to dilution at the bottom of the price chart; very tight money situation, lack of any but the most minimal buying from insiders; clinical targets (nasty scars) that even the largest and most well-funded bios have failed to crack; lack (at least so far) of any indication that other bios are interested; bungled early pr by management; etc.
In short, there is a huge gap between the bulls' view of what can and will be achieved and the bears' view of what is realistic to expect. Way more than half full or way more than half empty?
"For now, it's a stock caught in a swirling trading/shorting machine, where price level, trades, price movement relate neither to arms length genuine trading nor the fundamental potential of the science or RXI-owned IP."
Well, if you are convinced of that, just keep holding and buying as it falls. I think you might be correct. There does seem to me to be enough reasonable promise to this company to justify a higher price for the stock. I am, however, no longer as confident of that as I once was--no longer as confidence as I was that the lead technology can really meet its clinical targets. Therefore, I will no longer average down, though I will hold what I have.
Is is just amazing to me that the bears have been consistent winners here. I had thought that the announcement of the IND filing would put an end to the plunge. It didn't. Before that, I thought that the final disposition of Tang's preferred would stabilize things. It didn't.
No matter what plans are announced, what new initiatives are disclosed (such as Campachiara beng in charge of the retinal scarring design and implementation), or how much Geert talks about interest from other bios, this goes down.
I have decided to just hold it and see if it ever recovers. Selling now would not provide meaningful proceeds and things could turn around. As I have said before, concrete clinical results (such as meaningful retardation of nasty scars even after six months) will probably be needed. Just reiterating plans and trial design adaptations will not do it. Without positive and significant empirical results, the buyers will likely continue to go elsewhere.
Caveat: A deal with a big bio (especially with up front cash), even before good clinical results are announced, would also turn this tailspin around, imo.
"Do No Harm when making posts, otherwise just keep your negative thoughts to yourself if you are wanting this stock to go up instead of going down."
I want this stock to go up. I have a lot of shares. Still, I like serious, insightful discussions and that sometimes means I like to read comments--and even make comments--the pure pumpers would consider " negative." Some longs want to read nothing but pure pumping. They think that less than rev remarks will be "harmful."
I've got news for them, this message board has almost no impact on the share price and, in any case, would-be-longs are suspicious of pure pumping. Due diligence doesn't consist in reading pumping posts on Yahoo message boards.
We had a humungous amount of ecstatic pumping here over the past year--more, I would say, than bashes--and it didn't prevent the price from being in the thrty seven cent range.
What is the point of this board? In my mind it is to exchange information and learn.
I don't get your point newbie. I was pointing out that both would-be-longs and those who already hold positions here are just waiting for concrete news, clinical or deal news. How does that pertain to anything you said? I' m not stressed. I am just awaiting results like everybody else.
By the way newbie, since you have never visited this board before, what's with the insults you hurled my way? That's not good manners for somebody who just got here.
The ridiculous and childish negative posts are having no impact. The blissful pumping posts are having no impact. Would be longs and existing longs can read the press releases, conference transcripts, and 10Qs quite well. The conclusion they seem to have reached is: Wait and do nothing until concrete clinical or deal news is reported. We have an optimistic management but it must now prove itself.
Okay tene. I hope that it works because I am very long this stock. If it reduces CTGF, I hope it does so in sufficient amounts for a sufficient length of time. Of course, as you point out, we need to find the proper protocol. I just hope that CTGF is the sole relevant factor in scar growth and excessive scar growth. Stopping or at least severly restricting the growth of hypertrophic scars and keloids might be achievable solely through attacking CTGF. Or not.
Science--bio science or other kinds--is always a matter of showing that the theory (in our case, reducing CTGF significantly) is empirically borne out (that scarring is significantly reduced over an extended time.) I guess I am not really persuaded that "...the issue is the timing and amont of dosage to tame resurgence of CTGF." That seems to me to beg the question of whether or not CTGF is really the culprit (or the sole or main culprit) in nasty scarring.
Well, I hope you are right and Rxi Pharma finds the proper protocol. If ANY of the anti-scarring trials (dermal,or optical) succeed, we are absolutely golden.
Well rmsacc and biotechpicklist, the retinal scarring trials as well as the dermal scarring trials will set Rxi Pharma up for big time success, IF sd-rxrnai can be used to effectively down regulate scarring to a significant extent over an extended time period. The bulls here seem to be assuming that it can do that. So far, things don't look very promising in that respect, it looks to me.
The company has quit making rosy claims about the anti-scarring efficacy of sd-rxrnai. They say only that they are still trying to find a successful protocol. That, in my opinion, is why the price is still near its all time low. Tang helped bring the price down but Tang is not what is keeping it down now.